Michael Fifer, MD

Articles by Michael Fifer, MD

Aficamten Emerges as a Potential First-Line Therapy in Hypertrophic Cardiomyopathy

ByMichael Fifer, MD,Danielle Valletti, Assistant Editor

September 10th 2025

Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).

Latest Updated Articles

Michael Fifer, MD

Articles by Michael Fifer, MD

Aficamten Emerges as a Potential First-Line Therapy in Hypertrophic Cardiomyopathy

Latest Updated Articles

Trending on Pharmacy Times

FDA Approves Elinzanetant as First Nonhormonal Therapy for Menopause Vasomotor Symptoms

Fall 2025 Quiz: Test Your Pharmacy Knowledge!

Earlier Menopause, Reduced Cardiac Function Potentially Linked With Negative Impacts on Brain Health

Menopause Care Varies by Provider, Highlighting Need for Standardized Education

New Data Show Elinzanetant Is a Safe, Well-Tolerated Non-Hormonal Therapy for Menopausal Vasomotor Symptoms